Piramal Pharma Q4 Revenue Flat, FY26 PAT at -₹326Cr

Piramal Pharma reported flat Q4 revenue of ₹2,752Cr, with a full-year decline of 3% to ₹8,869Cr, impacted by CDMO destocking and soft ex-US anesthesia sales.
The company recorded a full-year net loss of ₹326Cr after a ₹196Cr exceptional impairment charge related to intangible assets under development.
EBITDA margin contracted to 13% for FY26 from 17% in FY25, though cost optimization efforts partly offset revenue pressures.
Management highlighted a recovery in biopharma funding, the completed Kenalog® acquisition, and expects growth acceleration across all businesses in FY27.